JP2018525703A - バイオマーカー測定の妥当性確認 - Google Patents

バイオマーカー測定の妥当性確認 Download PDF

Info

Publication number
JP2018525703A
JP2018525703A JP2017561708A JP2017561708A JP2018525703A JP 2018525703 A JP2018525703 A JP 2018525703A JP 2017561708 A JP2017561708 A JP 2017561708A JP 2017561708 A JP2017561708 A JP 2017561708A JP 2018525703 A JP2018525703 A JP 2018525703A
Authority
JP
Japan
Prior art keywords
biomarker
value
control value
control
values
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017561708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525703A5 (https=
Inventor
レオ、チャールズ、マクヒュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunexpress Pty Ltd
Original Assignee
Immunexpress Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901982A external-priority patent/AU2015901982A0/en
Application filed by Immunexpress Pty Ltd filed Critical Immunexpress Pty Ltd
Publication of JP2018525703A publication Critical patent/JP2018525703A/ja
Publication of JP2018525703A5 publication Critical patent/JP2018525703A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017561708A 2015-05-28 2016-05-20 バイオマーカー測定の妥当性確認 Pending JP2018525703A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015901982A AU2015901982A0 (en) 2015-05-28 Validating biomarker measurement
AU2015901982 2015-05-28
PCT/AU2016/050388 WO2016187655A1 (en) 2015-05-28 2016-05-20 Validating biomarker measurement

Publications (2)

Publication Number Publication Date
JP2018525703A true JP2018525703A (ja) 2018-09-06
JP2018525703A5 JP2018525703A5 (https=) 2019-06-27

Family

ID=57392259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017561708A Pending JP2018525703A (ja) 2015-05-28 2016-05-20 バイオマーカー測定の妥当性確認

Country Status (9)

Country Link
US (2) US20180107783A1 (https=)
EP (1) EP3304093B1 (https=)
JP (1) JP2018525703A (https=)
CN (1) CN108323184A (https=)
AU (1) AU2016267392B2 (https=)
CA (1) CA2986787A1 (https=)
DK (1) DK3304093T3 (https=)
HK (1) HK1249182A1 (https=)
WO (1) WO2016187655A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023169202A (ja) * 2017-06-13 2023-11-29 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
WO2025094604A1 (ja) * 2023-10-31 2025-05-08 アークレイ株式会社 検知方法、検知装置、検知システム、検知プログラム、及び記録媒体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
CN111094583A (zh) 2017-08-04 2020-05-01 十亿至一公司 与生物靶相关的定量中利用靶相关分子的测序输出确定和分析
CN111148844A (zh) 2017-09-01 2020-05-12 韦恩生物科技股份公司 鉴定和使用糖肽作为诊断和治疗监测的生物标记物
WO2019183052A1 (en) * 2018-03-19 2019-09-26 Sri International Methods and systems for biomarker analysis
CN109055535A (zh) * 2018-09-14 2018-12-21 北京泱深生物信息技术有限公司 血液中的分子作为诊断脓毒症的标志物
CN109374904A (zh) * 2018-10-29 2019-02-22 浙江医院 一种蛋白质类脓毒症标志物及其在严重脓毒症早期预警的应用及其筛选方法
US11170872B2 (en) 2019-11-05 2021-11-09 Apeel Technology, Inc. Prediction of latent infection in plant products
US11049590B1 (en) 2020-02-12 2021-06-29 Peptilogics, Inc. Artificial intelligence engine architecture for generating candidate drugs
WO2021202620A1 (en) * 2020-03-31 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Metabolomics approach combined with machine learning to recognize a medical condition
CN113488107B (zh) * 2021-07-07 2022-07-19 广州华银康医疗集团股份有限公司 筛选免疫组库测序生物标志物的方法、设备和存储介质
EP4195212A1 (en) * 2021-12-08 2023-06-14 A3P Biomedical AB (publ) Certainty-based medical conclusion model adaptation
CN114628024A (zh) * 2022-02-24 2022-06-14 重庆市急救医疗中心(重庆市第四人民医院、重庆市急救医学研究所) 一种生物标志物组在制备用于辅助筛查脓毒症的产品中的用途和辅助筛查方法及其系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077931A1 (en) * 2006-05-01 2011-03-31 Grimes F Randall Methods and apparatus for identifying disease status using biomarkers
WO2012068642A1 (en) * 2010-11-26 2012-05-31 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
JP2013509588A (ja) * 2009-10-29 2013-03-14 テシス バイオサイエンス， インコーポレイテッド ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー
US20140120545A1 (en) * 2011-04-18 2014-05-01 Diamir, Llc METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148339A1 (en) 2001-05-07 2003-08-07 Hrissi Samartzidou Artificial genes for use as controls in gene expression analysis systems
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20040180365A1 (en) * 2002-12-13 2004-09-16 Affymetrix, Inc. Methods and computer software products for gene expression data quality analysis
CA2577741A1 (en) 2004-08-18 2006-03-02 Abbott Molecular, Inc. Determining data quality and/or segmental aneusomy using a computer system
JP2008538007A (ja) * 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US20080213768A1 (en) * 2006-08-17 2008-09-04 Zhauhui Cai Identification and use of biomarkers for non-invasive and early detection of liver injury
DE102007010252B4 (de) 2007-03-02 2013-07-04 Sirs-Lab Gmbh Kontrollgene zur Normalisierung von Genexpressionsanalysedaten
CA2604317C (en) * 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
JP4666237B2 (ja) 2008-07-09 2011-04-06 ソニー株式会社 遺伝子検定方法、遺伝子検定プログラム及び遺伝子検定装置
US20120035860A1 (en) 2010-04-29 2012-02-09 Akmaev Viatcheslav R GC Wave Correction for Array-Based Comparative Genomic Hybridization
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
WO2013152989A2 (en) * 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
WO2013153461A2 (en) * 2012-04-13 2013-10-17 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
AU2014284124B2 (en) 2013-06-20 2020-03-12 Immunexpress Pty Ltd Biomarker identification
JP2017512304A (ja) * 2014-02-06 2017-05-18 イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ バイオマーカーシグネチャー法ならびにそのための装置およびキット
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110077931A1 (en) * 2006-05-01 2011-03-31 Grimes F Randall Methods and apparatus for identifying disease status using biomarkers
JP2013509588A (ja) * 2009-10-29 2013-03-14 テシス バイオサイエンス， インコーポレイテッド ２型糖尿病の予防に対して一貫した改善をもたらすタンパク質バイオマーカーおよび脂質代謝物バイオマーカー
WO2012068642A1 (en) * 2010-11-26 2012-05-31 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
US20140120545A1 (en) * 2011-04-18 2014-05-01 Diamir, Llc METHODS OF USING miRNA FROM BODILY FLUIDS FOR EARLY DETECTION AND MONITORING OF MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE (AD)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023169202A (ja) * 2017-06-13 2023-11-29 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
JP7401710B2 (ja) 2017-06-13 2023-12-19 ボストンジーン コーポレイション 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
WO2025094604A1 (ja) * 2023-10-31 2025-05-08 アークレイ株式会社 検知方法、検知装置、検知システム、検知プログラム、及び記録媒体

Also Published As

Publication number Publication date
AU2016267392B2 (en) 2021-12-09
US10719579B2 (en) 2020-07-21
AU2016267392A1 (en) 2017-12-07
WO2016187655A1 (en) 2016-12-01
EP3304093B1 (en) 2023-12-27
DK3304093T3 (da) 2024-02-12
CN108323184A (zh) 2018-07-24
US20160350477A1 (en) 2016-12-01
US20180107783A1 (en) 2018-04-19
EP3304093A1 (en) 2018-04-11
EP3304093A4 (en) 2019-02-06
CA2986787A1 (en) 2016-12-01
HK1249182A1 (zh) 2018-10-26

Similar Documents

Publication Publication Date Title
EP3304093B1 (en) Validating biomarker measurement
Moldovan et al. Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis
JP6775499B2 (ja) 肺がん状態の評価方法
US11776661B2 (en) Determination of MAPK-AP-1 pathway activity using unique combination of target genes
Pedersen et al. Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls
US20150080243A1 (en) Methods and compositions for detecting cancer based on mirna expression profiles
Shaughnessy et al. Identification of microRNAs in bovine faeces and their potential as biomarkers of Johne’s Disease
WO2013049152A2 (en) Methods for evaluating lung cancer status
Verboom et al. Profile of the SeptiCyte™ LAB gene expression assay to diagnose infection in critically ill patients
KR20250019610A (ko) 치료 모니터링을 위한 메틸화된 세포 유리 dna의 분자 계수
Kardos et al. Development and validation of a NanoString BASE47 bladder cancer gene classifier
CN117079723A (zh) 一种与肌萎缩侧索硬化症相关的生物标志物、诊断模型及其应用
Andersen et al. Pre-diagnostic trajectories of lymphocytosis predict time to treatment and death in patients with chronic lymphocytic leukemia
CN114990215A (zh) microRNA生物标志物在肺癌诊断或预测预后中的应用
US20240363197A1 (en) Methods for characterizing infections and methods for developing tests for the same
Wang Molecular Epidemiology
EP4652296A1 (en) Methods and systems for detecting and assessing liver conditions
US20240035090A1 (en) mRNA BIOMARKERS FOR DIAGNOSIS OF LIVER DISEASE
Tonelotto et al. Efficacy of Fluorecare SARS-CoV-2 Spike Protein Test Kit for SARS-CoV-2 detection in nasopharyngeal samples of 121 individuals working in a manufacturing company
CN116254335B (zh) Adam12生物标志物在冠状动脉扩张症诊断中的应用
US20230175064A1 (en) Methods and systems for monitoring organ health and disease
US20250316381A1 (en) Assessment of Relative Quantitative Effect of Somatic Point Mutations at the Individual Tumor Level for Prioritization
CN113557307B (zh) 端粒相关变量的测定方法及其在端粒相关疾病的诊断和/或预后中的用途
CN117305444A (zh) 利用癌症中剪接异常的短外显子辅助癌症诊断和预后
IL325275A (en) Methods and systems for classifying tumor tissue samples

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210402